NASDAQ · Biotechnology

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) Stock

$2.31 +4.05% NASDAQ: LABT Healthcare

This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C.

Valuation

MetricValue
Price$2.31
Market Cap$4.04M
P/E Ratio-0.60
P/B Ratio—
P/S Ratio—
EPS (TTM)$-3.26
52-Week High$98.20
52-Week Low$1.66
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE—
ROA-507.35%
ROCE—
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity—
Current Ratio0.02

Latest News

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria PR Newswire · Jul 22, 2026 Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel PR Newswire · Jul 15, 2026 CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics Zacks Small Cap Research · Jul 13, 2026 Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance PR Newswire · Jul 7, 2026 Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire · Jun 26, 2026

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio—
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held48.67%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
Blue Trust, Inc.112026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Lakewood-Amedex Biotherapeutics Inc. Common Stock

This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.

Lakewood-Amedex Biotherapeutics Inc. Common Stock is led by CEO Kelvin Cooper, headquartered in US, publicly traded since 2026.

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) stock trades at $2.31 with a market capitalization of $4.04M. The stock is valued at a price-to-earnings (P/E) ratio of -0.60. Over the past 52 weeks the stock has ranged between $1.66 and $98.20, and currently trades 97.6% below its 52-week high.

On profitability, Lakewood-Amedex Biotherapeutics Inc. Common Stock generates an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.lakewoodamedex.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides